Zydus Lifesciences gets USFDA’s final nod for Minocycline Hydrochloride Extended-Release tablets

19 Jun 2023 Evaluate

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Minocycline Hydrochloride Extended-Release Tablets USP, 55 mg, 65 mg, and 115 mg (USRLD: Solodyn Tablets, 55 mg, 65 mg, and 115 mg). Minocycline Hydrochloride Extended-Release is used to treat moderate to severe acne in people 12 years and older. Minocycline belongs to a class of drugs known as tetracycline antibiotics. The product will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).

Minocycline Hydrochloride Extended-Release Tablets USP, 55 mg, 65 mg, and 115 mg had annual sales of $0.7 million in the United States (IQVIA MAT April 2023). The group now has 372 approvals and has so far filed over 442 ANDAs since the commencement of the filing process in FY 2003-04.  

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

875.50 2.55 (0.29%)
21-Jan-2026 11:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1621.00
Dr. Reddys Lab 1157.40
Cipla 1376.80
Zydus Lifesciences 875.50
Lupin 2149.35
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×